Cite
APA Citation
Wen, P. Y., de Groot, J., Battiste, J. D., Goldlust, S. A., Garner, J., Simpson, J., Olivero, A., & Cloughesy, T. (n.d.). p05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status. Neuro-oncology, 21, iii35. http://access.bl.uk/ark:/81055/vdc_100109738728.0x00000d